Patent classifications
A61K36/16
COMPOSITION FOR IMPROVED ENERGY, FOCUS AND CLARITY
A composition comprising: a racetam; an extract of Mucuna Pruriens; S-Adenosyl methionine; and caffeine; useful for improvement of alertness, physical endurance, sleep patterns, memory, perceptual acuity, and/or for increasing energy.
COMPOSITION FOR IMPROVED ENERGY, FOCUS AND CLARITY
A composition comprising: a racetam; an extract of Mucuna Pruriens; S-Adenosyl methionine; and caffeine; useful for improvement of alertness, physical endurance, sleep patterns, memory, perceptual acuity, and/or for increasing energy.
COMPOSITION FOR IMPROVED ENERGY, FOCUS AND CLARITY
A composition comprising: a racetam; an extract of Mucuna Pruriens; S-Adenosyl methionine; and caffeine; useful for improvement of alertness, physical endurance, sleep patterns, memory, perceptual acuity, and/or for increasing energy.
Gingko diterpene lactone composition
A Ginkgo diterpene lactone composition is provided. The extract can lower the neurological function score of a cerebral ischemia-reperfusion rat, reduce the cerebral ischemia area and the water content after brain tissue edema, improve SOD activity, and decrease the MDA content. The composition can inhibit rabbit platelet aggregation induced by PAF and ADP inducers at different time points so as to reduce the maximum aggregation rate. In addition, experiments show that the effect of each monomer compound in the Ginkgo diterpene lactone composition is significantly increased at certain proportion.
Gingko diterpene lactone composition
A Ginkgo diterpene lactone composition is provided. The extract can lower the neurological function score of a cerebral ischemia-reperfusion rat, reduce the cerebral ischemia area and the water content after brain tissue edema, improve SOD activity, and decrease the MDA content. The composition can inhibit rabbit platelet aggregation induced by PAF and ADP inducers at different time points so as to reduce the maximum aggregation rate. In addition, experiments show that the effect of each monomer compound in the Ginkgo diterpene lactone composition is significantly increased at certain proportion.
METHODS FOR TREATING ALZHEIMER'S DISEASE
The present invention provides a method of treating or delaying the onset of Alzheimer's disease or other neurological diseases in a patient having or at risk of developing Alzheimer's disease or other neurological diseases comprising administering to the subject an effective amount of an anti-angiogenic agent. In particular, the present invention provides a method of treating and/or delaying the onset of Alzheimer's disease or other neurological diseases by inhibiting Angiopoietin-2 mediated Tie-2 angiogenic pathway comprising administering to the subject an effective amount of an inhibitor of the Angiopoietin-2 mediated Tie-2 angiogenic pathway.
METHODS FOR TREATING ALZHEIMER'S DISEASE
The present invention provides a method of treating or delaying the onset of Alzheimer's disease or other neurological diseases in a patient having or at risk of developing Alzheimer's disease or other neurological diseases comprising administering to the subject an effective amount of an anti-angiogenic agent. In particular, the present invention provides a method of treating and/or delaying the onset of Alzheimer's disease or other neurological diseases by inhibiting Angiopoietin-2 mediated Tie-2 angiogenic pathway comprising administering to the subject an effective amount of an inhibitor of the Angiopoietin-2 mediated Tie-2 angiogenic pathway.
USE OF GINKGOLIDE A IN THE TREATMENT OF AUTISM
Use of ginkgolide A in the treatment of autism. Specifically, the present invention relates to use of ginkgolide A, a stereoisomer thereof, a crystal form thereof, a pharmaceutically acceptable salt thereof, a derivative thereof, an extract comprising ginkgolide A, or a combination thereof in the preparation of a pharmaceutical composition for the treatment of autism. The experiments have demonstrated that ginkgolide A can significantly alleviate the behavioral defects of autism, and ginkgolide A has the advantages of small dosage and high safety when treating autism, and is very suitable as a common medicine for the treatment of autism.
Composition for preventing or treating hearing loss, containing <i>Vitis vinifera </i>leaf extract as active ingredient
A composition for preventing or treating hearing loss, containing a Vitis vinifera leaf extract as an active ingredient, is disclosed. A pharmaceutical composition for preventing or treating hearing loss, containing the extract (a Vitis vinifera leaf extract) as an active ingredient, protects auditory hair cells in the cochlea and spiral ganglion cells from damage caused by noise and the like and effectively reduces the hearing threshold measured in the auditory nerves, thereby being usable as an agent for preventing or treating hearing loss.
Composition for preventing or treating hearing loss, containing <i>Vitis vinifera </i>leaf extract as active ingredient
A composition for preventing or treating hearing loss, containing a Vitis vinifera leaf extract as an active ingredient, is disclosed. A pharmaceutical composition for preventing or treating hearing loss, containing the extract (a Vitis vinifera leaf extract) as an active ingredient, protects auditory hair cells in the cochlea and spiral ganglion cells from damage caused by noise and the like and effectively reduces the hearing threshold measured in the auditory nerves, thereby being usable as an agent for preventing or treating hearing loss.